Tumor models for efficacy determination
- 1 October 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (10), 2435-2443
- https://doi.org/10.1158/1535-7163.mct-06-0391
Abstract
The first in vivo tumor models were developed in the mid-1960s. These models were mouse leukemia models grown as ascites. The growth pattern was like that of bacteria in vivo and therefore it was possible to apply similar mathematics of growth and response to these tumors as had been worked out for bacteria. Since the development of the murine leukemia models, investigators have devoted a large effort to modeling solid tumors in mice. There are now a variety of models including syngeneic mouse tumors and human tumor xenografts grown as s.c. nodules, syngeneic mouse tumors and human tumor xenografts grown in orthotopic sites, models of disseminated disease, “labeled” tumor models that can be visualized using varied technologies, and transgenic tumor models. Each of these types of models has advantages and disadvantages to the “drug hunter” searching for improved treatments. [Mol Cancer Ther 2006;5(10):2435–43]Keywords
This publication has 67 references indexed in Scilit:
- Inhibition of DNA Methyltransferase Activity Prevents Tumorigenesis in a Mouse Model of Prostate CancerCancer Research, 2006
- The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung CancerCancer Research, 2005
- New approaches for modelling cancer mechanisms in the mouseThe Journal of Pathology, 2005
- Preclinical models in cancer drug discovery and developmentEuropean Journal of Cancer, 2004
- Spontaneous and genetically engineered animal models: use in preclinical cancer drug developmentEuropean Journal of Cancer, 2004
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal of Cancer, 2004
- “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug developmentEuropean Journal of Cancer, 2004
- Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantagesEuropean Journal of Cancer, 2004
- Quantitative evaluation of anticancer agent activity in experimental animalsPharmacology & Therapeutics. Part A: Chemotherapy, Toxicology and Metabolic Inhibitors, 1977
- A new tissue culture isolation and explantation of the P388 lymphocytic neoplasm in a chemically characterized mediumExperimental Cell Research, 1963